WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202841

CAS#: 135598-68-4

Description: TAS-109, also known as DFP-10917 and CNDAC, is an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Nucleoside analogue TAS-109 is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.

Chemical Structure

CAS# 135598-68-4

Theoretical Analysis

MedKoo Cat#: 202841
Name: TAS-109
CAS#: 135598-68-4
Chemical Formula: C10H12N4O4
Exact Mass: 252.08585
Molecular Weight: 252.22668
Elemental Analysis: C, 47.62; H, 4.80; N, 22.21; O, 25.37

Price and Availability

Size Price Availability Quantity
100.0mg USD 950.0 2 Weeks
200.0mg USD 1450.0 2 Weeks
500.0mg USD 2650.0 2 Weeks
1.0g USD 3850.0 2 Weeks
2.0g USD 5950.0 2 Weeks
5.0g USD 9950.0 2 Weeks
Bulk inquiry

Synonym: TAS109; TAS109; TAS 109; DFP-10917; DFP 10917; DFP10917; CNDAC; Radgocitabine

IUPAC/Chemical Name: (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile


InChi Code: InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1

SMILES Code: N#C[C@@H]1[C@H](N2C=CC(N)=NC2=O)O[C@H](CO)[C@H]1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 252.22668 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

 1: Reeves MD. Increase in quality, but not quantity, of clinical trials in acute pain: 1992 versus 2007. Anesth Analg. 2009 Nov;109(5):1656-8. PubMed PMID: 19843804.

2: Taş A, Yağız R, Koçyiğit M, Karasalihoğlu AR. Primary nasopharyngeal tuberculosis. Kulak Burun Bogaz Ihtis Derg. 2009 Mar-Apr;19(2):109-11. PubMed PMID: 19796011.

3: Lubkowska A, Szygula Z, Klimek AJ, Torii M. Do sessions of cryostimulation have influence on white blood cell count, level of IL6 and total oxidative and antioxidative status in healthy men? Eur J Appl Physiol. 2010 May;109(1):67-72. Epub 2009 Sep 25. PubMed PMID: 19779735.

4: Cirit U, Bacinoglu S, Taş M, Demir K, Baş A, Ak K, Ileri IK. Evaluation of short estrus synchronization methods in dairy cows. Anim Reprod Sci. 2008 Dec;109(1-4):65-76. Epub 2007 Dec 28. PubMed PMID: 18276087.

5: Schaefer A, Matthess H, Pfitzer G, Köhle K. [Mental health and performance of medical students with high and low test anxiety]. Psychother Psychosom Med Psychol. 2007 Jul;57(7):289-97. Epub 2007 Mar 14. German. PubMed PMID: 17357900.

6: Seal JA, Doyle Z, Burgess JR, Taylor R, Cameron AR. Iodine status of Tasmanians following voluntary fortification of bread with iodine. Med J Aust. 2007 Jan 15;186(2):69-71. PubMed PMID: 17223766.

7: Ham BJ, Lee MS, Lee YM, Kim MK, Choi MJ, Oh KS, Jung HY, Lyoo IK, Choi IG. Association between the catechol O-methyltransferase Val108/158Met polymorphism and alexithymia. Neuropsychobiology. 2005;52(3):151-4. PubMed PMID: 16127282.

8: Tan CF, Piao YS, Kakita A, Yamada M, Takano H, Tanaka M, Mano A, Makino K, Nishizawa M, Wakabayashi K, Takahashi H. Frontotemporal dementia with co-occurrence of astrocytic plaques and tufted astrocytes, and severe degeneration of the cerebral white matter: a variant of corticobasal degeneration? Acta Neuropathol. 2005 Mar;109(3):329-38. Epub 2004 Nov 12. PubMed PMID: 15841415.

9: Stott K, Desmerger C, Holford P. Relationship among Lepista species determined by CAPS and RAPD. Mycol Res. 2005 Feb;109(Pt 2):205-11. PubMed PMID: 15839104.

10: Hong CC, Choi JW, Ahn CH. A novel in-plane passive microfluidic mixer with modified Tesla structures. Lab Chip. 2004 Apr;4(2):109-13. Epub 2004 Feb 10. PubMed PMID: 15052349.

11: Doyle Z, Seal J. The tasmanian iodine monitoring program in schools. Asia Pac J Clin Nutr. 2003;12 Suppl:S14. PubMed PMID: 15023603.

12: Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339-53. Review. PubMed PMID: 12570767.

13: Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. Am J Med Genet. 2000 Dec 4;96(6):771-4. PubMed PMID: 11121178.

14: Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exp Hypertens. 1999 Nov;21(8):1297-313. PubMed PMID: 10574414.

15: Solomon HM, Mullins RE, Lyden P, Thompson P, Hudoff S. The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin. Am J Clin Pathol. 1998 Apr;109(4):371-8. PubMed PMID: 9535388.

16: Carmi R, Barbash A, Mares AJ. The thoracoabdominal syndrome (TAS): a new X-linked dominant disorder. Am J Med Genet. 1990 May;36(1):109-14. PubMed PMID: 2139758.

17: Lominadze DG, Shinkarenko VS, Mamisashvili VA. [Study of the trajectory of erythrocyte movement in microvessels using a method of automatic image analysis]. Biull Eksp Biol Med. 1990 Apr;109(4):343-4. Russian. PubMed PMID: 2386823.

18: Loiselle CG, Dawson C. Toronto Alexithymia Scale: relationships with measures of patient self-disclosure and private self-consciousness. Psychother Psychosom. 1988;50(2):109-16. PubMed PMID: 3255977.

19: Tas K. [Diagnostic problems in a patient with hematuria]. Ned Tijdschr Geneeskd. 1965 Dec 18;109(51):2455-8. Dutch. PubMed PMID: 5852449.


100.0mg / USD 950.0

Additional Information

TAS-109 is a novel deoxycitidine analogue with unique mechanism of action. Brief exposure to high concentrations of TAS-109 inhibits DNA polymerase resulting in S-phase arrest, while prolonged exposure to TAS-109 at low concentration causes DNA fragmentation, G2/M phase arrest and apoptosis. TAS-109 demonstrated activity in tumor xenografts resistant to other deoxycitidine analogs. CI of TAS-109 is feasible and well tolerated with myelosuppression as main DLT. The recommended doses are 2 mg/m²/day and 3 mg/m²/day on the 14-day and 7-day CI schedules respectively. Preliminary activity was suggested. PD data demonstrate biological activity at the tested doses. see http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/2577.